Sarah Siederer

1.0k total citations · 1 hit paper
20 papers, 713 citations indexed

About

Sarah Siederer is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Sarah Siederer has authored 20 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Physiology and 3 papers in Molecular Biology. Recurrent topics in Sarah Siederer's work include Asthma and respiratory diseases (7 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers) and Respiratory and Cough-Related Research (3 papers). Sarah Siederer is often cited by papers focused on Asthma and respiratory diseases (7 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers) and Respiratory and Cough-Related Research (3 papers). Sarah Siederer collaborates with scholars based in United Kingdom, United States and Australia. Sarah Siederer's co-authors include Rodger Kempsford, Andrew I. Bayliffe, William Powley, Aili L. Lazaar, Germain Poirier, Brian Zeno, Virginia Norris, Kelly Hardes, Akram Khan and David Fairman and has published in prestigious journals such as Critical Care, Clinical Pharmacokinetics and British Journal of Clinical Pharmacology.

In The Last Decade

Sarah Siederer

20 papers receiving 700 citations

Hit Papers

A pilot clinical trial of recombinant human angiotensin-c... 2017 2026 2020 2023 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome
    2017 452 citations Akram Khan, Brian Zeno et al. Critical Care profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Siederer United Kingdom 9 354 230 177 115 109 20 713
Luni Chen Sweden 7 137 0.4× 142 0.6× 99 0.6× 67 0.6× 23 0.2× 11 439
Kacper Lechowicz Poland 10 328 0.9× 106 0.5× 30 0.2× 166 1.4× 40 0.4× 14 677
Bruno Revol France 13 165 0.5× 76 0.3× 81 0.5× 49 0.4× 21 0.2× 43 608
Brian Zeno United States 5 354 1.0× 79 0.3× 15 0.1× 113 1.0× 95 0.9× 9 549
Julián Ruiz‐Galiana Spain 11 143 0.4× 52 0.2× 177 1.0× 74 0.6× 22 0.2× 26 572
Munekazu Ryuzaki Japan 15 135 0.4× 89 0.4× 55 0.3× 53 0.5× 206 1.9× 58 564
Alberto Fortini Italy 14 123 0.3× 86 0.4× 32 0.2× 133 1.2× 189 1.7× 48 615
Mark Hepokoski United States 12 84 0.2× 102 0.4× 121 0.7× 38 0.3× 32 0.3× 21 495
Luca Soraci Italy 12 103 0.3× 65 0.3× 125 0.7× 110 1.0× 38 0.3× 49 596
Michael Kassirer Israel 12 52 0.1× 145 0.6× 39 0.2× 36 0.3× 87 0.8× 28 601

Countries citing papers authored by Sarah Siederer

Since Specialization
Citations

This map shows the geographic impact of Sarah Siederer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Siederer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Siederer more than expected).

Fields of papers citing papers by Sarah Siederer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Siederer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Siederer. The network helps show where Sarah Siederer may publish in the future.

Co-authorship network of co-authors of Sarah Siederer

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Siederer. A scholar is included among the top collaborators of Sarah Siederer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Siederer. Sarah Siederer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nijjar, Jagtar Singh, et al.. (2024). Randomized, placebo‐controlled study on the effects of intravenous GSK3858279 (anti‐CCL17) on a battery of evoked pain tests in healthy participants. Clinical and Translational Science. 17(9). e13873–e13873. 2 indexed citations
2.
Oliver, Victoria, Sarah Siederer, Anthony Cahn, et al.. (2023). Exploring the role of ex vivo metabolism on blood and plasma measurements of oxytocin among women in the third stage of labour: A post hoc study. British Journal of Clinical Pharmacology. 89(12). 3669–3680. 3 indexed citations
3.
4.
Gajewska‐Knapik, Katarzyna, Kirsten R. Palmer, Anthony Cahn, et al.. (2023). Pharmacokinetics and safety of inhaled oxytocin compared with intramuscular oxytocin in women in the third stage of labour: A randomized open‐label study. British Journal of Clinical Pharmacology. 89(12). 3681–3689. 5 indexed citations
5.
Hall, David A., Philipp Badorrek, Dominik Berliner, et al.. (2021). Effects of Recombinant Human Angiotensin-Converting Enzyme 2 on Response to Acute Hypoxia and Exercise: A Randomised, Placebo-Controlled Study. Pulmonary Therapy. 7(2). 487–501. 4 indexed citations
6.
7.
8.
Fernando, Disala, Sarah Siederer, Ian Schneider, et al.. (2017). Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 Study. EBioMedicine. 22. 249–255. 20 indexed citations
9.
Smith, John A., Lorcan McGarvey, Huda Badri, et al.. (2017). Effects of a novel sodium channel blocker, GSK2339345, in patients with refractory chronic cough. International Journal of Clinical Pharmacology and Therapeutics. 55(9). 712–719. 32 indexed citations
10.
Khan, Akram, Brian Zeno, Timothy E. Albertson, et al.. (2017). A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care. 21(1). 234–234. 452 indexed citations breakdown →
11.
Allen, Ann, Sarah Siederer, & Shuying Yang. (2016). Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma. International Journal of Clinical Pharmacology and Therapeutics. 54(4). 269–281. 2 indexed citations
12.
Siederer, Sarah, Ann Allen, & Shuying Yang. (2015). Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. European Journal of Drug Metabolism and Pharmacokinetics. 41(6). 743–758. 9 indexed citations
13.
Kempsford, Rodger, Virginia Norris, & Sarah Siederer. (2012). Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulmonary Pharmacology & Therapeutics. 26(2). 256–264. 60 indexed citations
14.
Harrell, Andrew W., Sarah Siederer, Graeme Young, et al.. (2012). Metabolism and Disposition of Vilanterol, a Long-Acting β2-Adrenoceptor Agonist for Inhalation Use in Humans. Drug Metabolism and Disposition. 41(1). 89–100. 45 indexed citations
15.
16.
Siederer, Sarah, et al.. (2011). Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man. 38. 821. 2 indexed citations
17.
18.
19.
20.
Siederer, Sarah, et al.. (2006). Clinical Pharmacology of Cilomilast. Clinical Pharmacokinetics. 45(3). 217–233. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luni Chen Breakdown of academic impact, for papers by Kacper Lechowicz Breakdown of academic impact, for papers by Bruno Revol Breakdown of academic impact, for papers by Brian Zeno Breakdown of academic impact, for papers by Julián Ruiz‐Galiana Breakdown of academic impact, for papers by Munekazu Ryuzaki Breakdown of academic impact, for papers by Alberto Fortini Breakdown of academic impact, for papers by Mark Hepokoski Breakdown of academic impact, for papers by Luca Soraci Breakdown of academic impact, for papers by Michael Kassirer
Rankless by CCL
2026